Message from Management
Juzen has a confidence that we can provide the value-added services for various customer requests based on the global standard policy.
We, Juzen was established in 1950 as a manufacturer to make antihistaminic drug and penetrate the organic intermediate field in 1956 when Juzen manufactured monochloroacetic acid. After that, Juzen expands the business field to contract manufacture service for value added intermediates and APIs.
By the way, Juzen thinks that pharmaceutical companies in the world tend to outsource and accelerate this speed. Under this situation, we are committed to make continuous efforts to be the best partner of CDMO (Contracted Development Manufacturing Organization) . We responds to the various demands of out-sourcing at any stage from new drug development to the drug already on the market with leveraging the our experiences and know-how as a "CDMO" of API or key intermediates.
In 2015, Juzen built API plants adapted to the cutting edge GMP which can manufacture many kinds of API to play a role as a manufacture base for the world pharmaceutical companies.
Owing to the completion for the plant, Juzen can enhance QA system not only from soft point of view but also from hardware.
Additionally, Juzen has become to be able to tackle from the new drug development stage to the manufacture for the commercial products by collaborating with small-size plant adjusting investigational new drug GMP based on the synthetic organic chemistry technology.
Furthermore, Juzen will be able to bring up an attractive price by collaborating with existing multi pharmaceutical intermediate plants and manufacture for many kinds of products.
From 2017, we started offering of various CMC services to meet the request from customers, which covers development of synthetic procedure, development of analytical procedure and CMC developmental supports in many aspects based on our rich experience and expertise.
Juzen has a confidence that we can provide the valued added services for various customer requests based on the global standard policy.
